thalidomide has been researched along with Cancer of Colon in 18 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Screening for cancer revealed coexistence of two neoplasms: colon sigmoid cancer (operated on 6 weeks after pulmonary embolism onset), and multiple myeloma (treated successfully with thalidomide and dexamethasone)." | 3.75 | [Pulmonary embolism as a first manifestation of synchronous occurrence of two neoplasms]. ( Elikowski, W; Krokowicz, P; Lewandowska, M; Małek, M; Piotrowska-Stelmaszyk, G; Zawilska, K, 2009) |
| "Thalidomide is an anti-inflammatory agent that potentiates the anti-tumour activity of DMXAA but decreases induction of TNF in plasma." | 1.35 | Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. ( Baguley, BC; Ching, LM; Chung, F; Liu, J, 2008) |
| "Thalidomide has been shown to have both antiinflammatory and antiangiogenic effects in several diseases." | 1.31 | Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. ( Han, DS; Jin, SH; Kim, TI; Kim, WH; Shin, SK, 2002) |
| "05) increased the elimination half-life (t1/2) of DMXAA in plasma (413 micromol/l), liver (132 micromol/l), and spleen (77 micromol/l), and significantly (P < 0." | 1.31 | Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. ( Baguley, BC; Ching, LM; Kestell, P; Muller, G; Palmer, BD; Paxton, JW; Zhao, L, 2000) |
| "Thalidomide did not increase intra-tumoural TNF-alpha production induced with LPS, in sharp contrast to that obtained with DMXAA." | 1.30 | Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. ( Baguley, BC; Browne, WL; Cao, Z; Ching, LM; Joseph, WR; Mountjoy, KG; Palmer, BD, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 13 (72.22) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vo, MC | 1 |
| Nguyen-Pham, TN | 1 |
| Lee, HJ | 1 |
| Jaya Lakshmi, T | 1 |
| Yang, S | 1 |
| Jung, SH | 1 |
| Kim, HJ | 1 |
| Lee, JJ | 1 |
| Galustian, C | 1 |
| Meyer, B | 1 |
| Labarthe, MC | 1 |
| Dredge, K | 1 |
| Klaschka, D | 1 |
| Henry, J | 1 |
| Todryk, S | 1 |
| Chen, R | 1 |
| Muller, G | 2 |
| Stirling, D | 1 |
| Schafer, P | 1 |
| Bartlett, JB | 1 |
| Dalgleish, AG | 2 |
| Liu, Y | 1 |
| Li, H | 1 |
| Matsui, O | 1 |
| Elikowski, W | 1 |
| Lewandowska, M | 1 |
| Małek, M | 1 |
| Krokowicz, P | 1 |
| Piotrowska-Stelmaszyk, G | 1 |
| Zawilska, K | 1 |
| Liu, WM | 1 |
| Gravett, AM | 1 |
| Kinuya, S | 1 |
| Kawashima, A | 1 |
| Yokoyama, K | 1 |
| Koshida, K | 1 |
| Konishi, S | 1 |
| Watanabe, N | 1 |
| Shuke, N | 1 |
| Bunko, H | 1 |
| Michigishi, T | 1 |
| Tonami, N | 1 |
| Raje, N | 1 |
| Anderson, KC | 1 |
| Jin, SH | 1 |
| Kim, TI | 1 |
| Han, DS | 1 |
| Shin, SK | 1 |
| Kim, WH | 1 |
| Pathak, RD | 1 |
| Jayaraj, K | 1 |
| Blonde, L | 1 |
| Yang, SH | 1 |
| Lin, JK | 1 |
| Chen, WS | 1 |
| Chiu, JH | 1 |
| Chung, F | 2 |
| Palmer, BD | 5 |
| Muller, GW | 1 |
| Man, HW | 1 |
| Kestell, P | 2 |
| Baguley, BC | 6 |
| Ching, LM | 6 |
| Lang, NP | 1 |
| Liu, J | 1 |
| Xu, ZF | 1 |
| Gummer, BH | 1 |
| Joseph, WR | 2 |
| Browne, WL | 2 |
| Tchernegovski, R | 1 |
| Gregory, T | 1 |
| Cao, Z | 1 |
| Mountjoy, KG | 1 |
| Calder, K | 1 |
| Bruera, E | 1 |
| Zhao, L | 1 |
| Paxton, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Cancer of Colon
| Article | Year |
|---|---|
Thalidomide and immunomodulatory drugs as cancer therapy.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Humans; Immun | 2002 |
17 other studies available for thalidomide and Cancer of Colon
| Article | Year |
|---|---|
Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Co | 2017 |
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Female; Forkhead Transcription | 2009 |
The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Female; Image Processing, Compu | 2009 |
[Pulmonary embolism as a first manifestation of synchronous occurrence of two neoplasms].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Heparin, Low | 2009 |
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, W | 2011 |
Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Female; Humans; Iodine | 2002 |
Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells.
Topics: Colonic Neoplasms; Humans; Interleukin-1; Interleukin-8; NF-kappa B; Signal Transduction; Thalidomid | 2002 |
Thalidomide-associated hyperglycemia and diabetes: case report and review of literature.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Blood Glucose; Colonic Neoplasms; Diabetes Mel | 2003 |
Anti-angiogenic effect of silymarin on colon cancer LoVo cell line.
Topics: Angiogenesis Inhibitors; Cell Differentiation; Cell Movement; Colonic Neoplasms; Endothelial Growth | 2003 |
Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Drug Synergism; Enzyme-Linked Immunosorbent Ass | 2003 |
Molecular epidemiology: new insights into diagnosis and prognosis.
Topics: Alleles; Angiogenesis Inhibitors; Breast Neoplasms; Colonic Neoplasms; Female; Gene Expression; Glut | 2004 |
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Topics: Animals; Antineoplastic Agents; Body Temperature; Capillary Permeability; Colonic Neoplasms; Colorin | 2008 |
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Interactions; Mice; Mice, Inbred C57BL; Mice | 1995 |
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Synergism; Mice; Neoplasm Transplantation; P | 1998 |
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; D | 1999 |
Thalidomide for night sweats in patients with advanced cancer.
Topics: Adenocarcinoma; Cachexia; Colonic Neoplasms; Female; Humans; Hypnotics and Sedatives; Middle Aged; S | 2000 |
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bile; Colonic Neoplasms; Female; Half-Life; Mice; | 2000 |